{"product_id":"westpharma-swot-analysis","title":"West Pharmaceutical Services SWOT Analysis","description":"\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOutlines the strengths, weaknesses, opportunities, and threats of West Pharmaceutical Services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear, actionable template for prioritizing strategic initiatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eWest Pharmaceutical Services SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis you'll receive. The document below reflects the same quality and depth you’ll get after purchasing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003ch2\u003eSWOT Analysis Template\u003c\/h2\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eWest Pharmaceutical Services faces a dynamic market, balancing innovation with competitive pressures. Their strengths lie in their specialized expertise and strong customer relationships. Yet, they encounter threats from market volatility and regulatory hurdles.\u003c\/p\u003e\n\u003cp\u003eExplore the intricate interplay of internal capabilities and external market forces in the complete SWOT analysis. Gain deep strategic insights and a fully editable format for immediate application.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leadership and Reputation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWest Pharmaceutical Services dominates the market, especially in elastomer components for injectable drugs. Their reputation for top-notch quality and reliability is key in the strict pharma industry. This strength is evident in their financials; in 2023, they reported net sales of $3.07 billion. They hold strong, long-term partnerships with major pharmaceutical firms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWest Pharmaceutical Services boasts a diversified product portfolio. This includes stoppers, seals, and plungers. They also offer advanced delivery systems like self-injection devices. In 2024, sales of proprietary products increased by 10%. This diversification minimizes reliance on single products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Manufacturing and Supply Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWest Pharmaceutical Services' global manufacturing presence, spanning the Americas, Europe, and Asia, is a key strength. This strategic footprint enables the company to serve a diverse customer base efficiently. For example, in 2024, approximately 60% of sales came from outside the United States. This distribution reduces shipping expenses. West's proactive supply chain management ensures supply continuity, a crucial factor in today's market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocus on High-Value Products (HVP)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWest Pharmaceutical Services excels in High-Value Products (HVP), essential for complex injectable drugs, like biologics and GLP-1 medications. These HVPs boost profit margins and fuel revenue, driving growth. Innovation and R\u0026amp;D investments support this focus. West's HVP sales increased, representing a significant portion of its revenue. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eHVP sales account for a substantial part of West's revenue, reflecting their importance.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eContinued R\u0026amp;D investments ensure a pipeline of innovative HVP solutions.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eStrong focus on HVPs drives revenue growth and profitability.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWest Pharmaceutical Services showcases financial resilience, marked by a strong balance sheet and low debt levels. They have consistently produced robust operating cash flow, enabling them to fund strategic initiatives and return capital to shareholders. For instance, the company's total debt to equity ratio was 0.32 as of December 31, 2024. This financial health supports their ability to navigate economic uncertainties and seize growth opportunities. Their financial strength also provides flexibility for future investments. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eLow Debt Levels: Debt-to-equity ratio of 0.32 (December 2024).\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eStrong Cash Flow: Consistent operating cash flow generation.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eInvestment Capacity: Ability to fund strategic investments.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eShareholder Returns: Capacity for share repurchases.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWest Pharma's $3B Sales \u0026amp; Strategic Edge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWest Pharmaceutical Services benefits from its strong market position, particularly in elastomer components, thanks to its reputation for quality, which generated $3.07 billion in net sales in 2023. The company also has a diverse portfolio that includes stoppers, seals, and self-injection devices; in 2024, sales of proprietary products increased by 10%. West's global manufacturing footprint spanning Americas, Europe, and Asia streamlines distribution, where around 60% of sales come from outside of the U.S.\u003c\/p\u003e\n\u003cp\u003eThe focus on High-Value Products (HVP) is a strategic advantage. HVPs, crucial for complex injectable drugs like biologics, are supported by R\u0026amp;D, fueling revenue growth and profitability. West has a strong financial standing, including low debt levels (0.32 debt-to-equity ratio as of December 31, 2024) and robust cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eStrength\u003c\/th\u003e\n\u003cth\u003eDetails\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Leadership\u003c\/td\u003e\n\u003ctd\u003eDominance in elastomer components.\u003c\/td\u003e\n\u003ctd\u003eProvides strong revenue and reliability.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiversified Portfolio\u003c\/td\u003e\n\u003ctd\u003eIncludes stoppers, seals, plungers \u0026amp; devices.\u003c\/td\u003e\n\u003ctd\u003eReduces dependency on a single product line.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Manufacturing\u003c\/td\u003e\n\u003ctd\u003eManufacturing across Americas, Europe, \u0026amp; Asia.\u003c\/td\u003e\n\u003ctd\u003eEfficient distribution \u0026amp; supply chain management.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Key Customers and Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWest Pharmaceutical Services' dependence on key customers and markets presents a notable weakness. A significant portion of its revenue comes from a limited number of major pharmaceutical and biotech clients. For example, in 2024, the top 10 customers accounted for approximately 50% of net sales. Any shifts in these relationships or issues within those companies could severely impact West's financial performance. Furthermore, fluctuations in specific market segments, such as a slowdown in generic drug manufacturing, pose financial risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVulnerability to Inventory Destocking\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWest Pharmaceutical Services faces vulnerabilities from inventory destocking, where customers cut back on their stock. This leads to reduced order volumes. For instance, in Q1 2024, destocking affected sales. Such reductions create uncertainty in financial forecasts, impacting short-term revenue and earnings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSensitivity to Foreign Currency Exchange Rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWest Pharmaceutical Services generates substantial revenue internationally, exposing it to currency exchange rate risks. In 2024, approximately 40% of West's sales originated outside the U.S. Unfavorable currency shifts can reduce reported financial results. For instance, a strengthening U.S. dollar can diminish the value of international sales when translated back.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePotential for Margin Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eWest Pharmaceutical Services faces potential margin pressure. Gross profit margins have seen a slight decline recently. Rising costs of raw materials, energy, and labor are contributors. Pricing pressure from customers or competitors could further squeeze profits. This could impact financial performance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eGross profit margin decreased to 30.5% in Q1 2024, compared to 31.6% in Q1 2023.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRaw material costs rose by approximately 5% in 2023.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eLabor costs increased by about 7% in 2023.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain Disruptions and Geopolitical Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eWest Pharmaceutical Services faces supply chain vulnerabilities due to its global operations. Geopolitical instability or natural disasters can disrupt the flow of materials, impacting production. Such disruptions can lead to increased costs and decreased profitability. The company's dependence on international suppliers poses risks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eIn 2023, supply chain issues contributed to increased costs.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eGeopolitical tensions continue to threaten supply stability.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eWest's mitigation strategies include diversifying suppliers.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey Risks Facing the Pharma Giant\u003c\/h3\u003e\n\u003cp\u003eWest Pharma’s weaknesses include customer concentration risks, as a few clients drive significant sales. Inventory destocking affects short-term revenue. Currency exchange rate fluctuations from global sales also pose challenges. Moreover, rising raw material and labor costs impact margins. Lastly, supply chain disruptions due to global operations are vulnerabilities.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIssue\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer Concentration\u003c\/td\u003e\n\u003ctd\u003eSales dependence\u003c\/td\u003e\n\u003ctd\u003eTop 10 customers: ~\u003cstrong\u003e50%\u003c\/strong\u003e of 2024 sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory Destocking\u003c\/td\u003e\n\u003ctd\u003eReduced orders\u003c\/td\u003e\n\u003ctd\u003eImpacted Q1 2024 sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrency Exchange\u003c\/td\u003e\n\u003ctd\u003eFinancial results impact\u003c\/td\u003e\n\u003ctd\u003e~\u003cstrong\u003e40%\u003c\/strong\u003e sales outside the US\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMargin Pressure\u003c\/td\u003e\n\u003ctd\u003eProfit decline\u003c\/td\u003e\n\u003ctd\u003eGross margin: \u003cstrong\u003e30.5%\u003c\/strong\u003e in Q1 2024 (vs \u003cstrong\u003e31.6%\u003c\/strong\u003e in Q1 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply Chain\u003c\/td\u003e\n\u003ctd\u003eProduction disruption\u003c\/td\u003e\n\u003ctd\u003eSupply chain issues in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWest Pharma’s weaknesses include customer concentration risks, as a few clients drive significant sales. Inventory destocking affects short-term revenue. Currency exchange rate fluctuations from global sales also pose challenges. Moreover, rising raw material and labor costs impact margins. Lastly, supply chain disruptions due to global operations are vulnerabilities.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIssue\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer Concentration\u003c\/td\u003e\n\u003ctd\u003eSales dependence\u003c\/td\u003e\n\u003ctd\u003eTop 10 customers: ~50% of 2024 sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory Destocking\u003c\/td\u003e\n\u003ctd\u003eReduced orders\u003c\/td\u003e\n\u003ctd\u003eImpacted Q1 2024 sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrency Exchange\u003c\/td\u003e\n\u003ctd\u003eFinancial results impact\u003c\/td\u003e\n\u003ctd\u003e~40% sales outside the US\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMargin Pressure\u003c\/td\u003e\n\u003ctd\u003eProfit decline\u003c\/td\u003e\n\u003ctd\u003eGross margin: 30.5% in Q1 2024 (vs 31.6% in Q1 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply Chain\u003c\/td\u003e\n\u003ctd\u003eProduction disruption\u003c\/td\u003e\n\u003ctd\u003eSupply chain issues in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":56069130617216,"sku":"westpharma-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/westpharma-swot-analysis.png?v=1749381066","url":"https:\/\/swotanalysistemplates.com\/products\/westpharma-swot-analysis","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}